Fremanezumab
- TRADE NAMES: Ajovy (Teva); TEV-48125 (Teva)
- INDICATIONS: Migraine in adults
- CLASS: Calcitonin gene-related peptide (CGRP) receptor antagonist, Monoclonal antibody
- HALF-LIFE: ~31 days
FDA APPROVAL DATE: 09/14/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
There are no adequate data on the developmental risk associated with the use of fremanexumab in pregnant women. The long half life of fremanezumab should be a consideration for women who are pregnant or plan to become pregnant while using fremanezumab.
Contraindicated in patients with serious hypersensitivity to fremanezumab or to any of the excipients.
Please login to see the rest of this drug profile
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
LOCAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fremanezumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)Page last updated 03/09/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric